Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.

Author in
AI & Digital Bioeconomy & Society Startups & Deals NeuroTech Clinical Trials Biotech Manufacturing & Pharma 4.0 Tools & Methods HealthTech Aging & Longevity Contract Research Novel Therapeutics Marketing & E-commerce

Recent articles from Andrii

Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains

OpenAI and Retro Biosciences have released new findings from a joint effort in AI-driven protein engineering. Using GPT-4b micro, a biology-specialized variant of GPT-4o, the team designed two modified versions of Yamanaka factors, RetroSOX and RetroKLF, that showed over 50-fold …

How AI Is Transforming Medicinal Chemistry Between Discovery and Manufacture

In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic bottlenecks, expensive building blocks, low-yield reactions, and complications during scale-up for manufacturing can turn promising drug candidates into abandoned projects.

Synchron Becomes First to Achieve Native Thought-Control of Apple iPad Using Brain-Computer Interface

The New York-based medtech Synchron, a brain-computer interface (BCI) company backed by DARPA, Gates Frontier, and Bezos Expeditions, has become the first to publicly demonstrate native thought-based control of an Apple iPad. The demonstration, featuring a participant with ALS, marks …

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

No Clear Winner: 7-Year Brain Study Tests Rival Theories of Consciousness

A global team of researchers has carried out what may be the most ambitious attempt yet to test two of the most influential theories of consciousness: Integrated Information Theory (IIT) and Global Neuronal Workspace Theory (GNWT). Published today in Nature …

Study: Trust in Scientists Post-Pandemic Remains High, but Public Wants More Engagement

Led by researchers from Harvard University, ETH Zurich, and the University of Zurich, a recent international study sheds light on public perceptions of scientists and their role in society. This large-scale research, which engaged over 71,922 respondents …

Recursion and Faro Health Partner to Reimagine Clinical Trial Design with AI

Faro Health has partnered with Recursion to streamline clinical protocol design using Faro's AI-driven platform.

Eli Lilly Acquires Scorpion Therapeutics' Oncology Program for $2.5 Billion

Eli Lilly announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program for up to $2.5 billion, expanding its oncology pipeline with STX-478, a differentiated PI3Kα inhibitor currently in Phase 1/2 clinical trials.

Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases

Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory conditions. The partnership focuses on developing oral STAT6 small-molecule inhibitors and targeted protein degraders. STAT6 is a transcription factor …

Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation

Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including GENEVA OS, Green Button, and the Atropos Evidence Network. The partnership focuses on rapid cohort creation, advanced analytics, and generating …